AGRX - Agile Therapeutics: Managing A Position Ahead Of Twirla's Launch
- Agile Therapeutics is preparing to launch their first FDA approved product, Twirla. If all goes well, Twirla could quickly establish a foothold in a $4.1B addressable market.
- Launching an FDA approved product is not easy and has plenty of unknowns. I point out some things to keep an eye out for before and after Twirla's launch.
- AGRX has been a great investment over the past two years and could provide additional upside. I discuss how I intend to manage my remaining shares and possibly reload on AGRX.
For further details see:
Agile Therapeutics: Managing A Position Ahead Of Twirla's Launch